Oragenics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- $7M
- Website
- http://www.oragenics.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
- Conditions
- Mild Traumatic Brain Injury, Concussion
- Interventions
- Drug: Neurosteroid enantiomer
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06870240
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
- Conditions
- Oral Mucositis
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03234465
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸UF Health Cancer Center, Orlando, Florida, United States
Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)
- Conditions
- Oral Health
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Oragenics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01520974
- Locations
- 🇺🇸
University of Washington, Scool of Dentistry, Regional Clinical Dental Research Center, Seattle, Washington, United States
News
Oragenics Advances ONP-002 to Phase II Trial for Concussion Treatment
Oragenics has submitted an Investigator's Brochure for Phase II clinical trial of ONP-002, a novel intranasal neurosteroid targeting mild traumatic brain injury treatment in Australia.
Oragenics and BRAINBox Solutions Partner to Develop First Integrated Concussion Diagnosis and Treatment Platform
Oragenics and BRAINBox Solutions have formed a strategic partnership to create the first comprehensive concussion management platform, combining diagnostic biomarkers with intranasal therapy ONP-002.
Oragenics Advances ONP-002 for Concussion Treatment, Targets Phase II Trials in Australia
Oragenics is set to begin Phase II clinical trials in Australia for ONP-002, a treatment for mild traumatic brain injury, with first patient dosing aimed for late Q1 or early Q2 2025.
Oragenics Announces Termination of President's Employment Agreement and Provides Business Update
Oragenics Inc. terminated its President's employment agreement, as disclosed in a recent SEC filing, marking a significant leadership change.
Oragenics' ONP-002 Shows Promise for Concussion Treatment, Prepares for Phase II Trials
Oragenics' ONP-002, a neurosteroid delivered intranasally, is advancing to Phase II clinical trials for treating moderate to severe concussions.